Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis

Targeting of estrogen receptor is commonly used as a first-line treatment for hormone-positive breast cancer patients, and is considered as a keystone of systemic cancer therapy. Likewise, HER2-targeted therapy significantly improved the survival of HER2-positive breast cancer patients, indicating t...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical Society transactions Vol. 48; no. 2; p. 657
Main Author: Lev, Sima
Format: Journal Article
Language:English
Published: England 29.04.2020
Subjects:
Animals
Cell Line, Tumor
Cell Membrane - metabolism
Drug Resistance, Neoplasm
ErbB Receptors - metabolism
Female
Humans
Molecular Targeted Therapy
Oncogenes
Transcriptome
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - metabolism
EGFR
drug resistance
target therapy
ISSN:1470-8752, 1470-8752
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeting of estrogen receptor is commonly used as a first-line treatment for hormone-positive breast cancer patients, and is considered as a keystone of systemic cancer therapy. Likewise, HER2-targeted therapy significantly improved the survival of HER2-positive breast cancer patients, indicating that targeted therapy is a powerful therapeutic strategy for breast cancer. However, for triple-negative breast cancer (TNBC), an aggressive breast cancer subtype, there are no clinically approved targeted therapies, and thus, an urgent need to identify potent, highly effective therapeutic targets. In this mini-review, we describe general strategies to inhibit tumor growth by targeted therapies and briefly discuss emerging resistance mechanisms. Particularly, we focus on therapeutic targets for TNBC and discuss combination therapies targeting the epidermal growth factor receptor (EGFR) and associated resistance mechanisms.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1470-8752
1470-8752
DOI:10.1042/BST20191055